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Background: Proliferative vitreoretinopathy (PVR) is the commonest cause of late anatomical failure in rhegmatogenous
retinal detachment. Visual and anatomical outcomes remain poor despite advances in vitreoretinal surgical techniques
with reported primary failure rates of up to nearly 50%. Numerous adjunctive medications have been evaluated in
clinical trials with no agent gaining widespread acceptance and use.
This study was designed to investigate the benefits of using a slow-release dexamethasone implant delivered
intra-operatively in patients undergoing vitrectomy surgery for retinal detachment with established PVR.
Methods/design: For the study, 140 patients requiring vitrectomy surgery with silicone oil for retinal detachment
with established PVR will be randomised to receive either standard treatment or study treatment in a 1:1 treatment
allocation ratio. Both groups will receive the standard surgical treatment appropriate for their eye condition and routine
peri-operative treatment and care, differing only in the addition of the supplementary adjunctive agent in the
treatment group. The investigated primary outcome measure is stable retinal reattachment with removal of silicone
oil without additional vitreoretinal surgical intervention at 6 months.
Discussion: This is the first randomised controlled clinical trial to investigate the use of an adjunctive slow-release
dexamethasone implant in patients undergoing vitrectomy surgery for retinal detachments with proliferative
vitreoretinopathy.
Trial registration: EudraCT No: 2011-004498-96.Background
Proliferative vitreoretinopathy (PVR) is the most common
cause of late anatomic failure in retinal detachment
surgery and is generally regarded as having an incidence
of 5% to 11% of all rhegmatogenous retinal detachments
[1]. PVR can be considered a maladapted wound healing
response in the retina, which results in the formation of
fibrocellular membranes on both surfaces of the retina and
the posterior hyaloid face. Contraction of these membranes
can result in distortion of the normal retinal topography
with visually detrimental sequelae, and/or tractional retinal
detachment, with the reopening of pre-existing breaks
or the formation of new ones.* Correspondence: philip.banerjee@moorfields.nhs.uk
1Moorfields Eye Hospital NHS Foundation Trust, City Road, EC1V 2PD
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reproduction in any medium, provided the orPVR represents a difficult vitreoretinal surgical challenge
and despite the improvements in vitreoretinal surgery, a
significant number of cases fail to achieve reattachment.
Multiple surgeries are frequently required to eventually
achieve final retinal attachment with poor visual results
and unsatisfactory binocular visual outcomes [2-4]. Add-
itionally, PVR management is costly in patient time and
health-care resources [3].
Numerous adjunctive medications have been previously
evaluated in clinical trials [5-12], yet no effective and safe
adjunct has gained widespread acceptance to improve
surgical and visual outcomes. The proposed study is a
large-scale prospective randomised controlled clinical trial
to determine the efficacy of Ozurdex as an adjunctive
medication. A positive result of the study would have an
immediate clinical application worldwide.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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PVR peri-retinal membranes comprise four categories of
cells; retinal pigment epithelium, glial, inflammatory and
fibroblastic cells. These cells proliferate and may also be
contractile and are thus targets for anti-proliferative
agents. There is also a notable inflammatory component
to the PVR process with marked blood-retinal barrier
breakdown and intraocular fibrin formation. Thus both
cellular proliferation and the intraocular inflammatory
response are realistic targets for adjunctive treatments
in PVR.
Steroid treatment can potentially influence both the
inflammatory and proliferative components of PVR.
Experimental work has substantiated the theory that
corticosteroids can reduce Müller cell proliferation [13]
and reduce the severity of PVR [14-16].
Previous small-scale, uncontrolled clinical studies of
PVR have suggested intravitreal crystalline cortisone
was well tolerated in PVR cases undergoing vitrectomy
[17] and that systemic prednisolone [18], infused dexa-
methasone [19] and intravitreal triamcinolone [20] may
reduce the severity of PVR although none of these
studies were of sufficient power to provide a definitive
answer. A small prospective non-comparative clinical
study [21] concluded that intravitreal triamcinolone may
have some benefit as an adjunct in non-trauma-related
established PVR; however, this was contradicted by a
small randomised controlled trial [22] where no add-
itional benefit in surgical outcome was found. Both
groups concluded that further larger studies were required
to answer the question definitively.
The relatively short therapeutic duration of action of
triamcinolone may offer an explanation as to why it has
not emerged as a definitive adjunct, and the adoption of
a longer-acting sustained-release preparation may offer
additional advantages.
Investigational medicinal product
OzurdexW is an intravitreal implant containing 700 μg
of dexamethasone in a slow-release preparation. It is
indicated for the treatment of adult patients with macula
oedema following retinal vein occlusion (either branch or
central) [23], and inflammation of the posterior segment
of the eye presenting as non-infectious uveitis [24]. It is in-
creasingly being administered to treat the aforementioned
retinal conditions and has a good local and systemic safety
profile [23,24]. It is particularly useful in patients who
have isolated ocular disease especially unilateral, providing
an anti-inflammatory and anti-proliferative efficacy equal
to or greater than that achieved with systemic administra-
tion while avoiding the unwanted systemic side effects of
steroid use.
A study comparing the pharmacokinetics of this
dexamethasone preparation in vitrectomised and non-vitrectomised experimental eyes concluded there was a
similar vitreoretinal pharmacokinetic profile [25]. The
clinical safety profile and therapeutic benefit of the
investigational medicinal product (IMP) in patients
who have previously undergone vitrectomy surgery has
been reported [26-28]. The IMP reaches a therapeutic
concentration shortly after administration and peaks at
2 months, thus adequately covering the active PVR
process, proffering additional advantages over shorter-
acting agents.
Objectives
Primary objective
The primary objective is to test the hypothesis that an
adjunctive slow-release dexamethasone implant, given at
the time of surgery, can improve the anatomical outcome
of vitreoretinal surgery for established PVR and that there
will be stable retinal reattachment with removal of silicone
oil without additional vitreoretinal surgical intervention at
6 months.
Secondary objectives
The secondary objectives are to determine whether an
adjunctive slow-release dexamethasone implant, given at
the time of surgery, has an effect on the following at 6
and 12 months following the primary study vitrectomy:
 visual acuity (Early Treatment Diabetic Retinopathy
Study (ETDRS) method)
 macula oedema and thickness (spectralis domain
optical coherence tomography (SD-OCT) analysis)
 development of overt PVR recurrence at any time
point
 complete retinal reattachment
 posterior (post equatorial) retinal reattachment
 tractional retinal detachment
 hypotony or raised intraocular pressure (IOP)
 macula pucker or epiretinal membrane (ERM)
 cataract
 quality of life as assessed by NEI VFQ25, SF36 and
depression screening questionnaires [29]
Methods/design
This phase III single-masked randomised control study
aims to determine whether there is a beneficial effect in
using a slow-release dexamethasone preparation as an
adjunctive treatment at the time of surgery in patients
with established PVR following rhegmatogenous retinal
detachment.
The 140 patients are to be divided into two equal
groups (treatment and control arm). They are recruited
for the study if they satisfy the inclusion and exclusion
criteria. Participants are masked to their treatment
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surgeon is masked until the time of IMP delivery.
Both groups will receive standard surgical treatment
and routine preoperative and postoperative treatment
and care comprising standard 3 port pars plana vitrectomy
(or gel trimming if the eye was previously vitrectomised)
and internal identification of retinal breaks; peeling of
anterior and posterior epiretinal membranes and removal
of subretinal membrane if required; relief of traction by
retinectomy or placement of a scleral buckle at the operat-
ing surgeon’s discretion; retinopexy to retinal breaks
and retinectomy edge by cryotherapy or laser; intraocular
tamponade using 1300 or 5000 centistoke silicone oil.
Intra-oil medication, the IMP, will be administered
through a sclerostomy prior to wound closure in the
treatment group.
A check for perfusion of the optic nerve head immedi-
ately after the injection of the IMP will be performed,
along with digital indentation to confirm a satisfactory
IOP once all scleral ports have been sutured. Biomicro-
scopy will be performed the following day to confirm
the position of the implant.
If a patient is rendered aphakic as part of the operative
procedure and they have been randomised to receive the
IMP, the study treatment will not be given [30,31], but
the patient will still be followed up as part of the study.
Removal of silicone oil (combined with cataract extrac-
tion plus intraocular lens implantation when applicable)
will be planned for 3 to 5 months after primary surgery.
On removal of oil, a second dexamethasone implant
will be administered with performance of the same
aforementioned safety monitoring. Again, if a patient is
rendered aphakic or an anterior chamber intraocular
lens is inserted as part of the operative procedure, and
the patient has been randomised to receive the IMP,
the study treatment will not be given. The patient will
still be followed up as part of the study.
Patients who do not satisfy the criteria for controlled
IOP preoperatively (see management of IOP), will not
receive their second IMP injection.
Study visits and assessment schedule
Postoperative study visits will not differ from the routine
schedule for vitreoretinal procedures at the study site for
the first 6 months that is day 1, day 10, day 30, 3 months
and 6 months. Further assessments will be scheduled for
9 and 12 months post initial surgery. The time window
allowed around these scheduled visits will be as follows:
day 10 (+/− 3 days), day 30 (+/− 7 days) and months 3,
6, 9 and 12 (+/− 14 days). At each scheduled postoperative
study visit, a full ophthalmic assessment will be com-
pleted, including slit lamp biomicroscopy (with indirect
binocular ophthalmoscopy when required) and recording
of parameters including ETDRS visual acuity, Goldmanapplanation tonometry, anterior segment assessment and
retinal attachment status. SD-OCT will be used to record
the central foveal thickness and total macula volume.
An additional study visit to assess IOP has been included
in the protocol schedule at day 60 postoperatively follow-
ing both the study vitrectomy and the removal of oil
procedure.
Silicone oil removal will not be considered a reopera-
tion and there will be routine subsequent follow-ups
until the patient can return to the study visit schedule.
Other vitreoretinal interventions (with the exception of
external retinal laser treatment, and macula ERM peel)
over the trial period will be considered reoperations and
recorded as such. Postoperative visits related to reopera-
tions, or any other attendance outside the study visit
schedule, will be recorded as ‘unscheduled visits’. Case re-
port forms (CRFs) identical in composition to the study
scheduled visit CRF will be completed and included in the
data analysis on completion of the study.
Following the final study visit at 12 months, partici-
pants will be discharged back to the care of their general
practitioner. Participants requiring ongoing ophthalmic
care will be followed up by their admitting consultant or
will be under the care of a more appropriate specialist
consultant, for example, a glaucoma specialist.
Management of intraocular pressure
The commonest significant side effect of this dexame-
thasone preparation is raised intraocular pressure (≥ 25
mmHg) and was reported to occur in approximately 25%
of participants in two phase III safety trials, peaking at
day 60 and returning to baseline at 6 months. The in-
vestigators will include the additional risk of a rise in
intraocular pressure with the trial treatment within the
participant information leaflet (PIL).
As stated, an additional study visit at day 60 to assess
IOP has been included in the protocol schedule and is
specified in the PIL. The investigators will, as much as
possible, adhere to an explicit management plan for
raised IOP. This plan has been approved by an external
glaucoma specialist and is given in Table 1.
Patients will be referred to the glaucoma service if:
1. IOP remains >25 mmHg on dual therapy
2. Long-term IOP management is required (that is >2
consecutive months of IOP lowering agents required
in the absence of an internal tamponade agent)
3. The investigators deem it in the patient’s interest
In the event where a patient’s IOP is >25 mmHg at the
time of listing for the procedure to remove silicone oil,
then additional topical ocular hypotensive agents may be
started or added and the patient’s surgery postponed by
up to 4 weeks until the IOP is ≤25 mmHg. Where the
Table 1 Algorithm for management of elevated intraocular pressure
Intraocular
pressure (mmHg)
Treatment Follow-up
≤ 25 None As per protocol schedule
>25 but <30 Single topical ocular hypotensive Within 6 weeks*
≥ 30 but <35 Dual topical ocular hypotensive Within 6 weeks
≥ 35 Oral administration of acetazolamide 500 mg and
dual therapy (recheck intraocular pressure within 2 hours)
After 2 hours:
1. Intraocular pressure <35 mmHg – oral administration of
Diamox 250 mg SR bd 5 days + dual topical therapy F/U 1 week
2. Intraocular pressure ≥35 mmHg – same day glaucoma service
input and/or consultant VR input
SR = slow release, bd = twice daily, F/U = follow up, VR = vitreoretinal.
*If intraocular pressure has not responded to single therapy or only partially responded, then a substitute agent will be tried or an additional agent
added, respectively.
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agents are required to control the IOP, then patients
randomised to receive the IMP will have their second
injection omitted. This will be recorded and reported
in the final manuscript.
Eligibility
Inclusion criteria
1. All patients with established PVR (Grade C) following
rhegmatogenous retinal detachment requiring surgery
with planned silicone oil tamponade
2. Ability to give informed consent
3. Willingness to accept randomisation and attend
follow-ups
Where the disease is bilateral at the time of screening,
the worst affected eye (in terms of severity of PVR) will
be included in the study.
Exclusion criteria
Individuals are excluded if they:
1. Are less than 18 years old
2. Have a history of open globe injury
3. Have a diagnosis of ocular hypertension and on two
or more pressure-lowering medications
4. Have a definite diagnosis of glaucoma and if in the
opinion of a glaucoma specialist, the patient is at
high risk of visual damage from raised IOP
5. Have uncontrolled uveitis
6. Have previous steroid-induced glaucoma
7. Have proliferative diabetic retinopathy
8. Are pregnant or breastfeeding females
(females with child-bearing potential must
have had a negative pregnancy test within
7 days of commencing the trial and agree to use
adequate contraception throughout the
duration of the trial)9. Have had a previous known adverse reaction to
the IMP
10. Have a suspected ocular or periocular infection
(for example, Herpes Simplex Virus, Varicella Zoster
Virus, mycobacterial or fungal disease)
11. Are aphakic or if a lensectomy is planned at time
of surgery
12. Have a pre-existing anterior chamber intraocular lensRecruitment and randomisation
Patient recruitment will only be done when the trial
has documented research and ethics committee (REC),
regulatory and local trust R&D approval. The study is
conducted in accordance with the International Confer-
ence on Harmonisation for Good Clinical Practice, as
set out in the European Union Clinical Trials Directive
(2001) and associated UK Regulations (2004). The study
will comply at all times with the Declaration of Helsinki
(2000).
All 140 participants will be identified and recruited
from outpatients and emergency referrals at Moorfields
Eye Hospital. At screening, a structured interview will
be conducted by research staff, which will include
questions on coexisting ocular pathology and previous
ophthalmic surgical procedures to confirm that all in-
clusion and exclusion criteria are satisfied.
Patients are then randomised to either the treatment
arm or control arm. The randomisation list was gener-
ated using permuted blocks of varying sizes and was
generated by a senior data manager independent of the
trial team. The list of 140 study IDs will be held by the
trial pharmacist, and following informed consent and
recruitment into the trial, participants will be allocated
to the lowest unused study ID. Out of hours (that is,
weekends and bank holidays) when access to the trial
pharmacist is limited, the next study ID in sequence
will be kept in a sealed envelope in a secure location
on site.
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An initial screening assessment will be performed prior to
recruitment to confirm that patients satisfy all inclusion
and exclusion criteria. This will include a full ophthalmic
examination with slit-lamp/indirect biomicroscopy and
consider the patient’s medical history and concomitant
medication.
Clinical findings documented as part of the routine
clinical care at the time of screening may be used to
populate data in the baseline CRF and used as part of
the study data (if collected within 1 week of the study
vitrectomy). This information may be collected prior to
informed consent for enrolment into the trial as no
additional intervention is performed outside routine
clinical care.
Baseline assessments will be performed within 1 week
of the scheduled operation date. This will include: pa-
tient demographics, past ocular history, logMAR visual
acuity (ETDRS method), slit lamp/indirect ophthalmic
examination (anterior and posterior segment assessment,
lens status, extent of retinal detachment, grade of PVR
[32]), SD-OCT-guided foveal thickness and volume, and
quality of life questionnaires.Masking
Participants are masked to their treatment allocation
until their completion of the study. The operating sur-
geon is masked until the end of the procedure just prior
to sclerostomy closure, to avoid any bias regarding surgical
management. It is not possible to mask the investigators
actively as the IMP may be visible during posterior
chamber assessment until its degradation. A placebo
vehicle was not used as a comparator as it was deemed
unethical due to lack of safety data, and the scientific
justification is that the treatment group can be com-
pared to the standard care group.Outcome measures
Primary
The primary outcome will be whether there is stable
anatomic reapposition of the retina to the retinal pig-
ment epithelium without additional vitreoretinal inter-
vention in the absence of an internal tamponade agent
at 6 months post study vitrectomy.
Secondary
Secondary outcomes will be performed at 6 and 12
months following the primary study vitrectomy:
 visual acuity: a comparison of the median visual
acuity and the proportion of patients in each group
achieving a visual acuity of 55 ETDRS letters or
better macula oedema and thickness (SD-OCT analysis),
that is the proportion of patients in each group with
a central A1 macula subfield measure of >300 μm
 the proportion of patients in each group who
develop overt PVR recurrence
 the proportion of patients in each group achieving
complete retinal reattachment
 the proportion of patients in each group achieving
stable posterior (post equatorial) retinal
reattachment
 the proportion of patients in each group with a
tractional retinal detachment
 the proportion of patients in each group who suffer
hypotony (defined as IOP <6 mmHg and/or raised
IOP (defined as >25 mmHg) at any time during the
study period
 the proportion of patients in each group who
develop macula pucker or epiretinal membrane
(ERM) and/or require macula ERM surgery at any
time during the study
 the proportion of patients in each group who require
cataract surgery at any time during the study
 quality of life assessment: a comparison of the
median or mean scores of both SF36 and VFQ25
between both groups and the proportion of patients
with severe depression [29]
Adverse events and safety reporting
Safety reporting will adhere to the sponsor’s standard
operating procedures and the trial team are confident
that means are in place to monitor, record and report
adverse events in line with guidelines issued by the
Medicines and Healthcare Products Regulatory Agency
(MHRA). There is an external data monitoring com-
mittee, who have an agreed charter. They will meet six
to twelve monthly or on an ad hoc basis as required.
Expected adverse events are as follows:
1. Cataract
2. Raised IOP
3. Hypotony
4. Sterile hypopyon
5. Retinal detachment
6. Uveitis
7. Further surgery
8. Glaucoma
9. Headache
10. Migraine
11. Vitreous opacities
More specifically, the recording of the severity of
raised IOP will be as follows:
Mild: >25 mmHg and <35 mmHg
Moderate: ≥35 mmHg
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ample, surgery or laser treatment) required to control the
elevated IOP acutely or long-term, during the study period
Unexpected adverse events will include:
1. Endophthalmitis
2. Systemic illness
3. Ocular vascular occlusion
4. Other
Trial size and timescale
Based on the results of the primary outcome measure
from a trial of the same patient group carried out in the
study centres [7], 66 patients per study arm are required
for a study power of 85% to detect, at the 5% level, a
50% improvement in the success of the adjunctive
regime (reducing failure from 49% to 24%). A 50%
reduction in failure would represent a marked clinical
benefit and would be likely to be adopted on a large
scale by vitreoretinal surgeons. Our pilot study has
shown that this is a realistic treatment difference.
Given a 5% loss to follow-up and protocol violations
(previous similar studies at Moorfields had rates of 3%
to 5% loss to follow-up or protocol violation [7-9]), this
gives a study total of 140 patients to be randomised.
Proposed timescale
Trial start: February 2012
Projected trial end: February 2015
Trial duration: 36 months
Duration of each patient’s participation: 12 months
Statistical analyses
The statistical analysis plan will be written in advance
of the data analysis by the trial statistician and will be
approved by the trial steering committee. Analysis will
be by intention to treat (ITT) to retain validity of the
randomisation process. The trial ITT population comprises
all randomised patients regardless of eligibility (inclusion/
exclusion) errors, post randomisation withdrawal and
whether the correct study treatments were received.
Data analysis will adhere to the CONSORT guidelines
for randomised controlled trials. The baseline charac-
teristics of the two groups will be compared to assess
the adequacy of randomisation.
Primary endpoint analysis
The chi-square test will be used to assess the statistical
significance of any observed differences between the
proportions of patients who ‘fail’ as defined by the pri-
mary outcome measures at 6 months in the two groups.
Logistic regression will be conducted to assess for any
baseline covariates believed to be associated with the
outcome.Secondary endpoint analysis
Summary statistics will be computed for changes in vis-
ual acuity for the two treatment groups at 6 and 12
months and the proportion of patients in each group
who suffer any adverse events will be summarised. The
exact binomial method will be used to compute 95%
confidence intervals. Summary statistics for all other
secondary outcomes will be provided by treatment group
and if statistical comparisons are made, results will be
reported as exploratory.Missing data
The sample size calculation assumed 5% of patients would
not provide an evaluable 6 month outcome. If data are
missing for any patients, reasons for missing data may
be important and these will be examined using logistic
regression of covariates on an indicator of missing data.
An available case analysis will be conducted together
with an ITT analysis (using imputation) and results
compared in a sensitivity analysis. Any deviations from
the statistical analysis plan will be described and justified
in the final report, as appropriate.Trial organisation and monitoring
Trial management committee
David Charteris: Chief investigator, Moorfields Eye Hos-
pital, London, UK
Philip Banerjee: Co-investigator, Moorfields Eye Hospital,
London, UK
Catey Bunce: Co-investigator and statistician, Moorfields
Eye Hospital, London, UK
Rachel Yoon: Trial pharmacist, Moorfields Eye Hospital,
London, UK
Nicola Harris: Trial manager, Moorfields Eye Hospital,
London, UK
T. Margaret Zvobgo: Research nurse, Moorfields Eye
Hospital, London, UKTrial steering committee
Professor Roger Hitchings: Chair, Emeritus Professor of
Glaucoma and Allied Studies, University College London
and Moorfields Eye Hospital, London, UK
Hadi Zambarakji: Consultant ophthalmologist and clin-
ical trialist, Whipps Cross University Hospital NHS
Trust, London, UK
Sue Beer: Lay person
David Charteris: Chief investigator, Moorfields Eye Hos-
pital, London, UK
Philip Banerjee: Co-investigator, Moorfields Eye Hos-
pital, London, UK
Catey Bunce: Co-investigator and trial statistician, Moor-
fields Eye Hospital, London, UK
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Timothy Jackson: Consultant vitreoretinal surgeon and
clinical trialist, King’s College London, UK
Professor Robert Maclaren: Nuffield Laboratory of
Ophthalmology and Oxford Eye Hospital Biomedical
Research Centre, University of Oxford, John Radcliffe
Hospital, Oxford, UK
Victoria Cornelius: Senior lecturer in medical statistics,
King’s College, London, UK
David Broadway: Consultant ophthalmologist, and
glaucoma specialist, Norfolk and Norwich University
Hospitals NHS Foundation Trust, UK
Trial documentation and data collection
The CRFs will be designed and produced by the inves-
tigators, according to the sponsor’s CRF template. The
final version will be approved by the sponsor. It will be
the responsibility of the investigators to ensure the
accuracy of all data entered onto the CRFs. A delegation
log will identify all trial personnel with responsibilities
for data collection and handling, including those who have
access to the trial database. Data handling will adhere
to the Data Protection Act, 1998.
Ethics and competent authority review
Applications to the UK’s main REC (NRES Committee
London – Central) and the local Moorfields Research
Management Committee have received favourable opin-
ions and a Clinical Trial Authorisation has been issued
by the MHRA.
Publication policy
The results of this study will be submitted for publication
in peer-reviewed medical journals regardless of whether
the findings are in favour of the trial intervention.
Discussion
This randomised controlled trial investigating the use of
a sustained-release dexamethasone implant will be the
first to evaluate its role as an adjunctive agent, in patients
undergoing vitreoretinal surgery for retinal detachment
with established PVR.
Our projected recruitment rate is based on a retro-
spective audit of the incidence of relevant cases at the
study site. Due to the poor prognosis associated with
current standard treatment, we expect a high recruit-
ment uptake following successful eligibility screening.
We remain optimistic that our recruitment target will be
met within the projected timescale.
We accept that although our inclusion criteria specifies
Grade C PVR requiring surgery with silicone oil, the co-
hort of participants is likely to be quite a heterogeneous
group. The severity of Grade C PVR can vary widely
throughout its sub-classification both in terms of extent(number of clock hours) and distribution (focal, diffuse,
anterior, posterior or subretinal). However, we expect
the adequacy of randomisation to compensate for this
and shall acknowledge any unequal weighting within
the groups as limitations of the study. We do, however,
accept that we may limit our sensitivity to small differences
between the two groups.
As this single centre study serves a wide geographical
catchment area with a broad patient demographic rep-
resentative of the UK, we do not expect the results to
provide a misleading estimate of treatment effect. Again,
we expect the adequacy of randomisation to compensate
for any variation of effect between ethnicities.
The authors acknowledge the limitations of a single
masked study, but have made every effort to reduce
investigator bias. As the IMP is no longer visible inside
the eye after approximately 8 weeks, it is unlikely that
the investigators will be aware of the treatment allocation
of the participant at the time of the primary and secondary
outcome assessments. The trial team considered using an
independent assessor of the primary outcome measure at
6 and 12 months, but felt that there was insufficient
evidence to suggest this was necessary and that it added
additional unjustifiable cost to the study.
Furthermore, by 1) masking the operating surgeon to
the treatment allocation until the end of the surgical
procedure and 2) explicitly defining the clinical findings
and adverse events and adhering to rigid management
protocols, (for example, for an IOP rise), we have limited
investigator bias as much as possible.
In summary, this is the first randomised controlled
clinical trial to investigate the use of an adjunctive slow-
release dexamethasone implant in patients undergoing
vitrectomy surgery for retinal detachments with prolifer-
ative vitreoretinopathy.
Trial status
The authors confirm that the trial was in active recruit-
ment at the time of manuscript submission.
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